From Research to Real Life: Transforming the Opportunity for Early Detection of Alzheimer's Disease with i-Function
When healthcare entrepreneur Peter Kallestrup co-founded i-Function®, he set out with a clear mission: to take powerful innovations confined to academic research and make them widely accessible tools for real-world cognitive health improvements. "What if we could leverage all that incredible research being done in universities and make it available so that it can benefit people in the real world?" Kallestrup asked. That question became the foundation of a company designed not just to innovate, but to democratize access to cognitive care.
i-Function ® is led by Kallestrup alongside two highly regarded academics, Dr. Philip D. Harvey , an expert in mental health and cognition, and Dr. Sarah J. Czaja , a leading authority in functional skills and aging research. Together, they have played a significant role in developing two flagship products: LASSI-D® and FUNSAT®. The former is a digital cognitive assessment tool; the latter, a digital functional skills assessment and training platform. While both serve different purposes, they both play a role in the process of assessing and supporting cognitive health.
LASSI-D ™ is the company's most recent innovation, a 15-minute digital cognitive assessment designed to detect the earliest stages of Mild Cognitive Impairment (MCI) and asymptomatic older adults with preclinical Alzheimer's disease. Dr. Sara J. Czaja explains, "It's like a Cardiac Stress Test for the brain. In just 15 minutes, we can tell with high probability whether your cognitive aging is likely normal or whether something else might be going on." The test is completely self-guided, with a human avatar serving the role of a human testing technician, leading users through the process privately and comfortably on most smart devices.
The value of early detection can't be overstated. According to research published in The Lancet , up to 40% of the risk of developing Alzheimer's can be mitigated through mid-late life lifestyle changes if the warning signs are caught early. "What would it be worth to have two more years with your mom, dad, or spouse with normal cognitive and functional abilities?" Dr. Harvey asks. "It's priceless. That's what we aim to offer, more time, more clarity, more hope."
FUNSAT ™, the company's original product, addresses functional skills: the day-to-day tasks that many with cognitive impairments struggle to perform. From managing medications to using online banking or navigating a phone voice menu, the tool helps individuals regain or build these critical capabilities. "It's not just about remembering or understanding something, it's about utilizing those cognitive skills in real life," says Dr. Harvey. "If we identify someone with early MCI using LASSI-D™, then FUNSAT™ becomes one of the suggested practical next steps in helping people live independently for longer."
While i-Function's tools have applications across many domains, clinical research, mental health treatment, rehabilitation, and aging care, their business model is currently B2B. Memory clinics, assisted living facilities, concierge medical practices, state mental health organizations, and pharma are among their key clients. "We are solving two problems," Kallestrup explains. "First, we give providers a fast, affordable, documented way to screen for early cognitive issues. Second, we offer an actionable path forward. That combination is rare."
The company has already seen early traction. FUNSAT™ is being used in several state-run mental health facilities and in clinical trials, and LASSI-D™ has entered its first wave of clinical adoption. The rollout is ongoing, with strong interest from both specialists and academic research centers alike. "Doctors don't always have time or the appropriate tools to assess cognitive health thoroughly or early enough, and many aren't necessarily comfortable making this assessment independently," Kallestrup notes. "With LASSI-D, they can run a fast, highly accurate screening with instant results and recommendations while patients wait. That's powerful."
Importantly, i-Function® is not focused on elite clinics or high-income users. "We are not building expensive tools for the wealthy," Peter Kallestrup, CEO of i-Function®, emphasizes. "This needs to be accessible to millions. Affordability is core to our mission." This ethos is one reason i-Function® in-licenses tools from leading research universities, then develops them into scalable, tech-enabled platforms. It's not about reinventing the science, it's about amplifying it.
That model has also gathered serious attention. The company's research has been supported by several highly competitive NIH grants. "Everything we do is backed by peer-reviewed science," Kallestrup says. "We have had the privilege of presenting on national stages, and last year we were cited in the National Institute of Aging annual report. But the most important recognition is seeing how our tools can change lives."
Looking ahead, i-Function® plans to continue to develop its current solutions as well as broaden its portfolio with new tools focused on the broad domain of cognitive health. The goal remains consistent: find transformative but underutilized academic discoveries and bring them to the people who need them most. For Kallestrup, it's a matter of urgency as much as innovation. "If you knew you were at risk of Alzheimer's, wouldn't you want to act now? Wouldn't you want the chance to intervene while it still matters?" he says. "That's the opportunity we are giving people. And we are just getting started."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Int'l Business Times
a day ago
- Int'l Business Times
Child Vaccine Coverage Faltering, Threatening Millions: Study
Efforts to vaccinate children against deadly diseases are faltering across the world due to economic inequality, Covid-era disruptions and misinformation, putting millions of lives at risk, research warned Wednesday. These trends all increase the threat of future outbreaks of preventable diseases, the researchers said, while sweeping foreign aid cuts threaten previous progress in vaccinating the world's children. A new study published in The Lancet journal looked at childhood vaccination rates across 204 countries and territories. It was not all bad news. An immunisation programme by the World Health Organization was estimated to have saved an estimated 154 million lives over the last 50 years. And vaccination coverage against diseases such as diphtheria, tetanus, whooping cough, measles, polio and tuberculosis doubled between 1980 and 2023, the international team of researchers found. However the gains slowed in the 2010s, when measles vaccinations decreased in around half of the countries, with the largest drop in Latin America. Meanwhile in more than half of all high-income countries there were declines in coverage for at least one vaccine dose. Then the Covid-19 pandemic struck. Routine vaccination services were hugely disrupted during lockdowns and other measures, resulting in nearly 13 million extra children who never received any vaccine dose between 2020 to 2023, the study said. This disparity endured, particularly in poorer countries. In 2023, more than half of the world's 15.7 million completely unvaccinated children lived in just eight countries, the majority in sub-Saharan Africa, according to the study. In the European Union, 10 times more measles cases were recorded last year compared to 2023. In the United States, a measles outbreak surged past 1,000 cases across 30 states last month, which is already more than were recorded in all of 2024. Cases of polio, long eradicated in many areas thanks to vaccination, have been rising in Pakistan and Afghanistan, while Papua New Guinea is currently enduring a polio outbreak. "Routine childhood vaccinations are among the most powerful and cost-effective public health interventions available," said senior study author Jonathan Mosser of the US-based Institute for Health Metrics and Evaluation (IHME). "But persistent global inequalities, challenges from the Covid pandemic, and the growth of vaccine misinformation and hesitancy have all contributed to faltering immunisation progress," he said in a statement. In addition, there are "rising numbers of displaced people and growing disparities due to armed conflict, political volatility, economic uncertainty, climate crises," added lead study author Emily Haeuser, also from the IHME. The researchers warned the setbacks could threaten the WHO's goal of having 90 percent of the world's children and adolescents receive essential vaccines by 2030. The WHO also aims to halve the number of children who have received no vaccine doses by 2030 compared to 2019 levels. Just 18 countries have achieved this so far, according to the study, which was funded by the Gates Foundation and the Gavi vaccine alliance. The global health community has also been reeling since President Donald Trump's administration drastically slashed US international aid earlier this year. "For the first time in decades, the number of kids dying around the world will likely go up this year instead of down because of massive cuts to foreign aid," Bill Gates said in a separate statement on Tuesday. "That is a tragedy," the Microsoft co-founder said, committing $1.6 billion to Gavi, which is holding a fund-raising summit in Brussels on Wednesday.
Int'l Business Times
2 days ago
- Int'l Business Times
From Research to Real Life: Transforming the Opportunity for Early Detection of Alzheimer's Disease with i-Function
When healthcare entrepreneur Peter Kallestrup co-founded i-Function®, he set out with a clear mission: to take powerful innovations confined to academic research and make them widely accessible tools for real-world cognitive health improvements. "What if we could leverage all that incredible research being done in universities and make it available so that it can benefit people in the real world?" Kallestrup asked. That question became the foundation of a company designed not just to innovate, but to democratize access to cognitive care. i-Function ® is led by Kallestrup alongside two highly regarded academics, Dr. Philip D. Harvey , an expert in mental health and cognition, and Dr. Sarah J. Czaja , a leading authority in functional skills and aging research. Together, they have played a significant role in developing two flagship products: LASSI-D® and FUNSAT®. The former is a digital cognitive assessment tool; the latter, a digital functional skills assessment and training platform. While both serve different purposes, they both play a role in the process of assessing and supporting cognitive health. LASSI-D ™ is the company's most recent innovation, a 15-minute digital cognitive assessment designed to detect the earliest stages of Mild Cognitive Impairment (MCI) and asymptomatic older adults with preclinical Alzheimer's disease. Dr. Sara J. Czaja explains, "It's like a Cardiac Stress Test for the brain. In just 15 minutes, we can tell with high probability whether your cognitive aging is likely normal or whether something else might be going on." The test is completely self-guided, with a human avatar serving the role of a human testing technician, leading users through the process privately and comfortably on most smart devices. The value of early detection can't be overstated. According to research published in The Lancet , up to 40% of the risk of developing Alzheimer's can be mitigated through mid-late life lifestyle changes if the warning signs are caught early. "What would it be worth to have two more years with your mom, dad, or spouse with normal cognitive and functional abilities?" Dr. Harvey asks. "It's priceless. That's what we aim to offer, more time, more clarity, more hope." FUNSAT ™, the company's original product, addresses functional skills: the day-to-day tasks that many with cognitive impairments struggle to perform. From managing medications to using online banking or navigating a phone voice menu, the tool helps individuals regain or build these critical capabilities. "It's not just about remembering or understanding something, it's about utilizing those cognitive skills in real life," says Dr. Harvey. "If we identify someone with early MCI using LASSI-D™, then FUNSAT™ becomes one of the suggested practical next steps in helping people live independently for longer." While i-Function's tools have applications across many domains, clinical research, mental health treatment, rehabilitation, and aging care, their business model is currently B2B. Memory clinics, assisted living facilities, concierge medical practices, state mental health organizations, and pharma are among their key clients. "We are solving two problems," Kallestrup explains. "First, we give providers a fast, affordable, documented way to screen for early cognitive issues. Second, we offer an actionable path forward. That combination is rare." The company has already seen early traction. FUNSAT™ is being used in several state-run mental health facilities and in clinical trials, and LASSI-D™ has entered its first wave of clinical adoption. The rollout is ongoing, with strong interest from both specialists and academic research centers alike. "Doctors don't always have time or the appropriate tools to assess cognitive health thoroughly or early enough, and many aren't necessarily comfortable making this assessment independently," Kallestrup notes. "With LASSI-D, they can run a fast, highly accurate screening with instant results and recommendations while patients wait. That's powerful." Importantly, i-Function® is not focused on elite clinics or high-income users. "We are not building expensive tools for the wealthy," Peter Kallestrup, CEO of i-Function®, emphasizes. "This needs to be accessible to millions. Affordability is core to our mission." This ethos is one reason i-Function® in-licenses tools from leading research universities, then develops them into scalable, tech-enabled platforms. It's not about reinventing the science, it's about amplifying it. That model has also gathered serious attention. The company's research has been supported by several highly competitive NIH grants. "Everything we do is backed by peer-reviewed science," Kallestrup says. "We have had the privilege of presenting on national stages, and last year we were cited in the National Institute of Aging annual report. But the most important recognition is seeing how our tools can change lives." Looking ahead, i-Function® plans to continue to develop its current solutions as well as broaden its portfolio with new tools focused on the broad domain of cognitive health. The goal remains consistent: find transformative but underutilized academic discoveries and bring them to the people who need them most. For Kallestrup, it's a matter of urgency as much as innovation. "If you knew you were at risk of Alzheimer's, wouldn't you want to act now? Wouldn't you want the chance to intervene while it still matters?" he says. "That's the opportunity we are giving people. And we are just getting started."
Int'l Business Times
18-06-2025
- Int'l Business Times
Passion, Plants, and Phase III: Devonian Health Group Is on a Mission to Disrupt Inflammation Therapy
While the industry might be dominated by synthetic compounds, billion-dollar VC funds, and long, uncertain development timelines, Devonian Health Group Inc. is proving there is another way. As a publicly traded company, under the leadership of its founder and CEO, Dr. André P. Boulet, Devonian has quietly advanced multi-target drug candidates and a cutting-edge cosmeceutical line, backed not by institutional investors but by a network of Canadian family offices made up of dentists, physicians, engineers, and entrepreneurs. Boulet's journey to this unconventional success story reads like a masterclass in risk, reinvention, and scientific conviction. "I'm a venture capitalist in my heart," Boulet says. "But I'm also a scientist. When I saw the anti-inflammatory results of this botanical extract technology from a university agriculture project, I knew this had real potential. So, I followed my instinct and took the risk." With a PhD in physiology-endocrinology, postdoctoral training in biochemistry and biophysics, and experience leading cardiovascular clinical research programs, Boulet's transition from academia to venture capital was swift. After climbing the pharmaceutical ladder and managing funds in Montreal, he exited his partnership and launched what would become Devonian Health Group in 2015. At its core, Devonian is a clinical-stage pharmaceutical company focused on autoimmune and inflammatory conditions, with its lead drug candidate, Thykamine ™, poised to enter Phase III clinical trials for atopic dermatitis and soon pediatric eczema. "Traditional pharma was built on the 'silver bullet,' one target, one mechanism," Boulet explains. "But now science is evolving. We're moving toward therapies that modulate multiple pathways. That's exactly what Thykamine does without shutting down important immune functions like TNF-alpha. That's why our efficacy is high, but side effects are minimal." What sets Devonian apart isn't just its marquee drug but the platform behind it. The company's patented SUPREX™ technology allows for water-based extraction, purification, and stabilization of Active Botanical Ingredients (ABIs) from plants and algae. These complexes modulate inflammation at the genetic level across multiple diseases, offering a broad pipeline of possibilities. To date, Thykamine™ has demonstrated strong results in its Phase II trial. Both gastrointestinal (ulcerative colitis) and dermatological (eczema) models have shown significant symptom relief and safety comparable to placebo. Remarkably, all this has been achieved without traditional VC backing. Boulet credits this to his deep network of entrepreneurial allies and his belief in business-first partnerships. "We've raised funds to advance to Phase III, built an extraction and production facility, and kept the company debt-free," he says. While the pharmaceutical arm garners headlines, Devonian's cosmeceutical division is equally ambitious. Operating under the Purgenesis™ brand, the company has developed a premium line of anti-aging creams containing its patented botanical ingredient R-Spinasome®, a photosynthetic cell extract with dynamic antioxidant properties. What makes Purgenesis™ unusual in the beauty space is its clinical rigor. Devonian has conducted peer-reviewed, pharma-grade clinical trials on the entire product line, something virtually unheard of in the cosmeceutical industry. "We've scientifically proven a reduction in wrinkles," says Boulet. "Not just pretty pictures, but peer-reviewed, published data. We're the only ones doing cosmeceuticals the pharma way." With day, night, and eye creams already developed and a professional-grade serum in the pipeline, Devonian is currently seeking commercial partners to bring Purgenesis™ to a global market hungry for results-backed skincare. Perhaps the most unusual aspect of Devonian's success is how personal it all feels. There are no Silicon Valley investors or hedge fund suits behind the curtain, just a network of entrepreneurs who believe in the mission. "Working with family offices is stimulating," Boulet says. "You get input from pharmacists, dentists, and industrialists. We face challenges together, and we have fun doing it." The company's headquarters in Québec includes a full-scale extraction and production facility, providing complete traceability from seed to pill. This vertical integration helps with both cutting costs, yes, but also ensuring product consistency. For Boulet, the journey has been one of passion and perseverance. "In life, there's always a risk," he reflects. "But if you surround yourself with the right people and believe in what you're building, that risk becomes your fuel. That's what Devonian is about: science, instinct, and community." As the company readies for Phase III trials in both pharmaceuticals and final-stage commercialization of its skincare line, Devonian Health Group stands as a testament to the power of conviction and the potential of plants to reshape the future of medicine.
